Gilead Sciences and partner Arcellx reported pivotal‑stage data for anito‑cel in multiple myeloma showing high overall response rates and substantial complete remissions: 96% response and 74% CR in a 117‑patient cohort. The companies presented the results at ASH and emphasized durability without new safety signals. Gilead needs anito‑cel to restore momentum in its blood‑cancer franchise and compete with existing CAR‑T therapies. Pivotal results will shape regulatory filings, reimbursement negotiations and launch sequencing; payers will focus on durability, manufacturing capacity, and comparative safety versus Carvykti and other CAR‑T options.